Author of

• 18374

  +

  P3.02b - Poster Session with Presenters Present (ID 494)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18438

    +

    P3.02b-064 - Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center (ID 6197)

    14:30 - 14:30  |  Author(s): J. Le Guévelou
    • Abstract

    Background:
    IPASS was the first study to demonstrate that EGFR-TKI was a valuable option as first line treatment for patients with advanced NSCLC and EGFR activating mutations (Mok TS et al, N Engl J Med 2009, 361 :947-57). To apply this strategy, it is essential that the results of the molecular analysis are quickly available. The objective of our study is first to determine which proportion of patients started EGFR-TKI as first line treatment during the last ten years in our institute, and secondly to calculate the time interval from the initial biopsy to the start of EGFR-TKI treatment.
    
    Methods:
    All patients with advanced stage NSCLC positive for EGFR activating mutation treated in our Comprehensive cancer center (Centre Francois Baclesse, Caen, France) from March 2006 to Decembre 2015 were retrospectively included. Patients may have been directly referred by their general practionner or by pulmonary physicians who had usually performed the diagnostic biopsy. In such a situation, the histological analysis was performed outside of our hospital. Molecular analysis was performed in both cases in our hospital. Demographic data were collected, the place where the histological analysis was performed, and time from biopsy to the start of first systemic treatment (EGFR-TKI or chemotherapy).
    
    Results:
    Eighty-six patients were included. Sixty-nine (80%) patients received EGFR-TKI as first line treatment (80%) and 17 (20%) did not. Reasons will be presented at meeting. The median time from initial biopsy to EGFR-TKI treatment was 26 days. The median time from initial biopsy to EGFR-TKI treatment was different according to the place where patients had their biopsy performed: 18 days when the biopsy was performed in our center vs 36 days when it was performed outside.
    
    Conclusion:
    A high proportion of patients could start EGFR-TKI as first line treatment (80%). Median time to treatment was longer in our center than what has been reported in a recent national survey (Barlesi F et al, Lancet 2016, 387 :1415-26). However, when the biopsy was performed in our hospital, the time to treatment was identical (18 days). Therefore, our collective efforts have now to focus on shortening the time to perform the molecular analysis when the histological analysis is performed outside of our hospital.